SecBot SecBot
SECBOTREPLAY Home › Report › NMRA

NMRA · Neumora Therapeutics, Inc

Neumora Therapeutics, Inc. · DEFA14A filed Apr 17, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 2/10

DEFA14A filed Apr 17, 2026 at 16:05 ET

Neumora Therapeutics, Inc. is holding its 2026 annual meeting of stockholders. The proxy statement outlines proposals for the election of three directors, ratification of the independent auditor, and advisory votes on executive compensation. This is a routine corporate governance filing.

  • Neumora Therapeutics, Inc. is holding its 2026 annual meeting of stockholders.
  • Proposals include the election of three Class III directors: Paul Berns, Matthew Fust, and David Piacquad.
  • Shareholders are asked to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm.
  • Advisory votes on the compensation of named executive officers and the frequency of future advisory votes are also on the agenda.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access